ESSEX BIO-TECHNOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.19 HKD | +0.46% |
|
-5.19% | -12.05% |
| Sales 2022 | 1.32B 168M | Sales 2023 | 1.71B 218M | Capitalization | 1.41B 181M |
|---|---|---|---|---|---|
| Net income 2022 | 225M 28.74M | Net income 2023 | 275M 35.13M | EV / Sales 2022 | 1.78 x |
| Net cash position 2022 | 53.76M 6.87M | Net cash position 2023 | 221M 28.23M | EV / Sales 2023 | 0.7 x |
| P/E ratio 2022 |
11
x | P/E ratio 2023 |
5.31
x | Employees | 1,481 |
| Yield 2022 |
1.55% | Yield 2023 |
3.61% | Free-Float | 45.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.46% | ||
| 1 week | -5.19% | ||
| Current month | -6.81% | ||
| 1 month | -7.20% | ||
| 3 months | -6.81% | ||
| 6 months | -20.36% | ||
| Current year | -12.05% |
1 week
2.17
2.32
1 month
2.142.36
Current year
1.962.65
1 year
1.963.80
3 years
1.968.29
5 years
1.968.29
10 years
1.969.60
| Managers | Title | Age | Since |
|---|---|---|---|
Hai Zhou Fang
CEO | Chief Executive Officer | 58 | 00-07-30 |
Qi Xue
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-04-08 |
Hian Leng Ngiam
BRD | Director/Board Member | 40 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mia Je Ngiam
FOU | Founder | 70 | 99-01-31 |
Lai Man Yau
BRD | Director/Board Member | 60 | 00-12-31 |
Mee Mooi Yeow
BRD | Director/Board Member | 72 | 04-09-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.00% | 117 M€ | +0.68% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.19 | +0.46% | 171 000 |
| 24-04-24 | 2.18 | -3.11% | 91,000 |
| 24-04-23 | 2.25 | -3.02% | 34,000 |
| 24-04-22 | 2.32 | +0.43% | 6,000 |
| 24-04-19 | 2.31 | 0.00% | 21,000 |
Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT
More quotes
Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.05% | 158M | |
| -2.86% | 87.31B | |
| +3.95% | 40.86B | |
| -21.94% | 29.36B | |
| +56.15% | 24.49B | |
| -5.41% | 17.31B | |
| -44.23% | 11.26B | |
| -17.60% | 11.62B | |
| -13.96% | 11.31B | |
| +6.74% | 8.31B |
- Stock Market
- Equities
- 1061 Stock
